National Bank of Canada
STOK icon

National Bank of Canada’s Stoke Therapeutics STOK Stock Holding History

National Bank of Canada’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262 Buy
+8
New +$257 ﹤0.01% 2937

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

National Bank of Canada's STOK Position: Q2 2026 in Review

National Bank of Canada opened a new position in Stoke Therapeutics (STOK) in Q2 2026: 8 shares worth $262. The stake represents ﹤0.01% of the portfolio and ranks #2937 among its holdings.

198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • National Bank of Canada held 8 shares of Stoke Therapeutics worth $262 as of Q2 2026.
  • Stoke Therapeutics was a new National Bank of Canada position in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2937 holding.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.